BACKGROUND Although running is a popular leisure-time physical activity, little is known about the long-term effects
Board reviewed and approved the study annually. All participants gave written informed consent for the examinations and follow-up study.
ASSESSMENT OF RUNNING. Running or jogging activity during the past 3 months was assessed at baseline by the physical activity questionnaire, including 4 questions about duration, distance, frequency, and speed as part of the medical examination.
For calculation of the total weekly running time, the average duration of running was multiplied by the frequency. For calculation of the total amount of running, the metabolic equivalent (MET) value for a given speed was multiplied by the weekly running time (6) . Participants were classified into 6 groups: nonrunners and 5 quintiles of weekly running time (minutes), distance (miles), frequency (times), amount (MET-minutes), and speed (miles/h) in runners. For complete analyses of running characteristics and mortality, we defined runners as those who reported all 4 detailed running questions and nonrunners as those who did not report any running questions. We also examined the associations between change in running behaviors and mortality in a subgroup of 20, 647 participants from the overall sample of 60,603 who received at least 2 medical examinations between 1974 and 2002 and were free from MI, stroke, or cancer at both examinations. We defined 4 categories of change in running behaviors using the baseline and last follow-up examination: "remained nonrunners" were nonrunners at both examinations, "became nonrunners" were runners only at the baseline examination, "became runners" were runners only at the last examination, and "remained runners"
were runners at both examinations. Total amount of other physical activities except running (cycling, swimming, walking, basketball, racquet sports, aerobic dance, and other sports-related activities) was classified into 3 groups: 0, 1 to 499, and $500 METminutes per week based on the Physical Activity Guidelines (3). To reduce confounding bias in the association between running and mortality, the total amount of other physical activities except running was adjusted in all multivariable regression models. Our physical activity assessment has been described elsewhere (7) and was formerly validated and shown to correlate to measured cardiorespiratory fitness and physiological variables (5, 8) . and had higher cardiorespiratory fitness levels ( Table 1) .
Compared with nonrunners, runners had 30%
and 45% lower risks of all-cause and CVD mortality, respectively, after adjustment for potential confounders ( Fig. 1) . These associations were consistent regardless of sex, age, BMI, health conditions, smoking status, and alcohol consumption. We estimated PAFs for running and other mortality predictors, such as smoking, overweight/obesity, and Values are mean AE SD or %. *Calculated as the weight in kg divided by the square of the height in m. †Defined as >14 and >7 alcohol drinks per week for men and women, respectively. ‡Total physical activity levels from other leisure-time activities except running. §Defined as systolic or diastolic blood pressure $140/90 mm Hg or history of physician diagnosis. kDefined as fasting glucose $126 mg/dl, current therapy with insulin, or history of physician diagnosis. ¶Defined as total cholesterol $240 mg/dl or history of physician diagnosis. #Defined as abnormal resting or exercise electrocardiogram, including rhythm and conduction disturbances and ischemic ST-T wave abnormalities. **Estimated from the final treadmill speed and grade during the maximal exercise test in a subsample of 50,995 participants.
MET ¼ metabolic equivalent.
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A U G U S T 5 , 2 0 1 4 : 4 7 2 -8 1 chronic diseases. Not running was almost as important as hypertension, accounting for 16% of all-cause and 25% of CVD mortality ( Table 2) . Also, nonrunners had 3 years' lower life expectancy compared with runners after adjustment for other mortality predictors.
In the dose-response analyses (Table 3) started running, and 13% continued running, indicating that the more consistent group was the inactive nonrunners. Compared with never-runners (nonrunners at both examinations), runners at 1 or both examinations were more likely to have lower mortality risk (Fig. 3) . Persistent runners over an drinks per week for men and women, respectively. BMI ¼ body mass index.
Running and Mortality average of 5.9 years, however, had the most significant mortality benefit, with 29% and 50% lower risk of all-cause and CVD mortality, respectively.
DISCUSSION
There were 3 major findings from this study (Central Illustration). First, runners had consistently lower risk of all-cause and CVD mortality compared with nonrunners. Second, running even at lower doses or slower speeds was associated with significant mortality benefits. Third, persistent running over time was more strongly associated with mortality
reduction.
An earlier study found a 39% lower risk of all-cause mortality in 538 runners who were $50 years of age Participants were classified into 6 groups: nonrunners and 5 quintiles of each running distance, frequency, total amount, and speed. All hazard ratios (HRs)
were adjusted for baseline age (years), sex, examination year, smoking status (never, former, or current), alcohol consumption (heavy drinker or not), other physical activities except running (0, 1 to 499, or $500 MET-min/week), and parental cardiovascular disease (CVD) (yes or no). The bars indicate 95% CI, and HRs are shown next to the bars. MET ¼ metabolic equivalent.
A large study of 416,175 adults found no additional mortality benefits for >50 min/day of vigorousintensity activities (15) . Recent studies have
proposed that excessive endurance sports may potentially induce adverse cardiovascular effects, such as arrhythmias and myocardial damage (16) (17) (18) (19) .
In contrast, there are studies showing a linear doseresponse relation between running and CVD risk, with more benefits at higher doses of running (20, 21) .
Thus, future studies are needed on this dose-response issue about whether there is an optimum upper limit of vigorous-intensity activities, beyond which additional activity provides no further mortality benefits.
Another short report from the Copenhagen City
Heart Study suggested a reduced mortality risk in 96 persistent male joggers (22) . Our study now suggests 
Running and Mortality
A U G U S T 5 , 2 0 1 4 : 4 7 2 -8 1 blood pressure, insulin sensitivity, and blood lipid profile (25) (26) (27) . There is also convincing observational evidence of the benefits of running in preventing chronic diseases, including coronary heart disease, stroke, hypertension, diabetes, and hypercholesterolemia (20, 21, 28) . Cardiorespiratory fitness is a strong morbidity and mortality predictor (9, 29, 30) , as a possible link between running and mortality (12) . We found that runners had approximately 30% higher cardiorespiratory fitness than nonrunners, and there was a linear increase of cardiorespiratory fitness with increasing running time (p < 0.001) at baseline (Fig. 4) . Every 30 min of additional weekly running time was associated with 0.5 MET higher cardiorespiratory fitness after accounting for age and sex (p < 0.001). We found no mortality benefits of running after further adjustment for cardiorespiratory fitness, as we have previously observed in total leisure-time physical activity and mortality (7). Therefore, it is possible that the mortality benefits of running may be explained by improved cardiorespiratory fitness. However, running is a behavior and cardiorespiratory fitness is a physiological attribute, which also is affected by other factors such as genotype. Thus, the current findings of no additional mortality benefits at the higher doses of running compared with lower doses of running may be related to other factors besides cardiorespiratory fitness. Hazard ratios (HRs) of all-cause and cardiovascular mortality by running characteristic (weekly running time, distance, frequency, total amount, and speed).
Participants were classified into 6 groups: nonrunners (reference group) and 5 quintiles of each running characteristic. All HRs were adjusted for baseline age (years), sex, examination year, smoking status (never, former, or current), alcohol consumption (heavy drinker or not), other physical activities except running (0, 1 to 499, or $500 MET-minutes/week), and parental history of cardiovascular disease (yes or no). All p values for HRs across running characteristics were <0.05 for all-cause and cardiovascular mortality except for running frequency of $6 times/week (p ¼ 0.11) and speed of <6.0 miles/h (p ¼ 0.10) for cardiovascular mortality. Abbreviation as in Figure 2 .
Strengths of this study include the very large sample size across a wide age range, extensive mortality follow-up, comprehensive analyses, and control of potential confounding factors including other nonrunning activities. In addition, we used various running characteristics to investigate the associations of both baseline and change in running with mortality.
STUDY LIMITATIONS. Our cohort consisted primarily of well-educated white adults from middle to upper socioeconomic strata, which may limit the generalizability of the findings. However, the potential for confounding by race/ethnicity, education, and income may be reduced in this population.
Physiological characteristics of our cohort are similar to those of other representative population samples (5) . Another limitation is the use of selfreported running during the past 3 months, which is longer than conventional physical activity questionnaires that include the previous 1 week or 1 month. Although running during the past 3 months could be more representative than running during the previous week or month, it may also increase the inaccuracy of self-report of running due to recall bias. People tend to overreport their leisuretime physical activities because it is a socially desirable behavior (31) . However, this overreporting bias would likely induce an underestimation of the true mortality benefits of running toward the null hypothesis. Runners are healthier than nonrunners in this population, with lower prevalence of chronic diseases at baseline ( Table 1) . It is possible that healthy people may run more, which could lead to reverse causality. However, we found consistent mortality benefits in runners in both healthy and unhealthy individuals (Fig. 1) . Also, we observed mortality benefits after additional adjustment for medical conditions ( Table 3) . Another potential limitation is the lack of adequate dietary information.
CONCLUSIONS
We found consistent long-term mortality benefits of leisure-time running. This study underlined that running even at relatively low doses (5 to 10 min/ day), below the current minimum guidelines of vigorous-intensity aerobic activity, was sufficient for substantial mortality benefits. Cardiorespiratory fitness was estimated from the final treadmill speed and grade during the maximal exercise test in a subsample of 50,995
participants. All p values for linear trend across weekly running time were <0.001 after adjustment for age and sex (not in sex-stratified analyses). Abbreviation as in Figure 2 .
